Abstract: This invention relates to a method for increasing the productivity of the secondary metabolite in a micro-organism, for example, the improvement of antibiotic producers by conferring drug-resistant mutations to micro-organisms.

Abstract: This invention relates to a method for increasing the productivity of the secondary metabolite in a micro-organism, for example, the improvement of antibiotic producers by conferring drug-resistant mutations to micro-organisms.

Abstract: The present invention provides a new antimicrobial compound WF14573, and a process for producing WF14573 by (a) culturing a WF14573A and/or B-producing microorganism in a nutrient medium and recovering WF14573A and/or B from the resultant cultured broth or (b) deacylating WF14573A and/or B in the presence of a microbial substance which is capable of deacylating WF14573A and/or B. Also provided are an antimicrobial agent comprising WF14573 and carrier(s), a pharmaceutical composition comprising an effective amount of WF14573 and pharmaceutically acceptable carrier(s), a method for killing microorganisms by applying WF14573 to the microorganisms, and use of WF14573 for the treatment of infectious diseases caused by pathogenic microorganisms.

Abstract: A composition for inhibiting cell damage comprising FR901459 Substance as following formula (I) or its salt in admixture with pharmaceutically acceptable carriers or excipients.

Abstract: A cyclic tetrapeptide compound and use thereof.

Abstract: The present invention provides a new bioactive compound of formula (I), which has an antimicrobial activity against pathogenic microorganisms, and a process for production thereof. Also provided are a pharmaceutical composition comprising the compound and pharmaceutically acceptable carrier, a use of the WF002 as a medicament and use of the compound for manufacture of the medicament for treatment of infectious disease.

Abstract: A compound having antimicrobial activity of the following general formula: ##STR1## wherein R.sup.1 is hydrogen or hydroxy, R.sup.2 is hydrogen or hydroxy, R.sup.3 is hydroxy or hydroxysulfonyloxy, with proviso that when R.sup.1 is hydrogen, R.sup.2 is hydrogen, or a phamaceutically acceptable salt thereof. The compound can be used in a method for treating infectious diseases caused by pathogenic microorganism.

Abstract: A polypeptide compound having antimicrobial activity of the following general formula: ##STR1## wherein R.sup.1 is hydrogen or acyl group, R.sup.2 is hydroxy or acyloxy,R.sup.3 is hydroxysulfonyloxy, andR.sup.4 is hydrogen or carbamoyl,with proviso thatR.sup.1 is not palmitoyl, when R.sup.2 is hydroxy,R.sup.3 is hydroxysulfonyloxy andR.sup.4 is carbamoyl,and a pharmaceutically acceptable salt thereof.

Abstract: Preparation of optically active 3-substituted azetidinones of the formula (I) ##STR1## in which R.sup.1 is a hydroxy-protective group wherein an allylic alcohol of the formula (II) ##STR2## is acylated, then subjected to asymmetric enzymatic hydrolysis yielding the R-allylic alcohol. The hydroxyl group is protected and then stereoselectively reacted with an amine which is subsequently cyclized to yield the desired 3-substituted azetidinone. Two new species of microorganisms have been isolated, Pimelobacter sp. No. 1254 and Bacillus megaterium No. 1253 which exhibit stereoselective esterase activity.

Abstract: The invention relates to a new compound, FR-900447, and pharmaceutically acceptable salts thereof having antimicrobial and antitumor activity, to a pharmaceutically composition thereof, and to a process for production thereof by culturing Streptomyces rubropurpureus FERM BP-584 in nutrient medium under aerobic condition.

Abstract: A pharmaceutical composition comprising an amount of a polypeptide of the formula: ##STR1## wherein R.sup.1 is hydrogen or an acyl group, R.sup.2 is hydroxy or an acyloxy group, R.sup.3 is hydrogen, hydroxy or hydroxysulfonyloxy, R.sup.4 is hydrogen or carbamoyl, and R.sup.5 and R.sup.6 are each hydrogen or hydroxy, with the proviso that (i) R.sup.2 is acyloxy when R.sup.3 is hydrogen, and (ii) R.sup.5 is hydrogen when R.sup.6 is hydrogen, or a pharmaceutically acceptable salt thereof, is useful in the prevention or treatment of Pneumocystis carinii infection.